Exact sciences corporation stock.

About EXAS. Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.Shares of Exact Sciences (NASDAQ:EXAS) were soaring 9.8% higher as of 3:38 p.m. EDT on Thursday. The company announced on Wednesday that new data for its ...Exact Sciences Corp Stock Price History. Exact Sciences Corp’s price is currently down 3.17% so far this month. During the month of November, Exact Sciences Corp’s stock price has reached a high of $68.02 and a low of $59.51. Over the last year, Exact Sciences Corp has hit prices as high as $100.77 and as low as $39.90. Year to date, Exact ...Get the latest information on Exact Sciences Corp (EXAS), a biotechnology company that develops and sells diagnostic tests for cancer screening and treatment. See its stock price, financial performance, earnings, balance sheet, cash flow, and more.Exact Sciences Corporation issued to certain of the selling stockholders of Paradigm an aggregate of 381,047 shares of common stock as initial merger consideration for their ownership in Paradigm. In addition, Exact Sciences Corporation withheld 45,338 shares of common stock payable as additional merger consideration to such selling ...

Analyst Recommendations on Exact Sciences Corporation. Goldman Sachs Adjusts Price Target on Exact Sciences to $90 From $100, Keeps Buy Rating. Nov. 03. MT. BofA Securities Cuts Price Target on Exact Sciences to $88 From $110, Maintains Buy Rating. Oct. 20. Whether you’re a solo small business owner or an administrative assistant at a huge multinational corporation, it can be important to make sure your office is stocked with the right tools to get the job done. Use these tips to choose the ri...

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited ...

Exact Sciences Corp. reported an EPS of $0 in its last earnings report, beating expectations of -$0.471. Following the earnings report the stock price went down -1.669%. Which hedge fund is a major shareholder of Exact Sciences Corp.?Stock Information · Financial Information · SEC Filings · Quarterly Results ... © Exact Sciences Corporation – 5505 Endeavor Lane - Madison, WI 53719. Powered By ...EXAS is the ticker symbol for Exact Sciences Corporation, a company that provides cancer screening and diagnostic test products. The stock price, news, quote, history and performance outlook of EXAS are shown on Yahoo Finance. See the latest earnings report, analyst report, research reports and more. How to Buy EXAS stock: 1. Open A Brokerage Account. To start investing, you will need a brokerage account. There are many brokerage companies on the market. However, they differ in the broker's commission, the number of markets available for investing, the complexity of the platform, and the ease of opening an account.Get the latest stock price, quote, news and history of Exact Sciences Corporation Common Stock (EXAS), a biotechnology company that develops and …

Share Price. EXACT Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer. It developed Cologuard, a screening test for the ...

Exact Sciences (EXAS) closed the most recent trading day at $66.26, moving -1.27% from the previous trading session. ... Exact Sciences Corporation (EXAS) : Free Stock Analysis Report.

Shares of Exact Sciences Corporation ( EXAS -0.26%) were down 11.3% for the week as of Thursday's close, according to data provided by S&P Global Market Intelligence. The healthcare company's ...Exact Sciences Corporation (NasdaqCM:EXAS) acquired Sampleminded, Inc. for $7.6 million on August 1, 2017. Under the terms, Exact Sciences paid $3.2 million in cash and issued 0.09 million restricted stock units.Oncotype DX ® Test Recognized as the 'Preferred' and Only Multigene Test to Predict Chemotherapy Benefit in Node-positive Early-stage Breast Cancer. Update based on first results from the independent RxPONDER study presented at the 2020 San Antonio Breast Cancer Symposium 1. Madison, Wis., March 31, 2021 - Exact Sciences today …Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2023 financial results after ...16 brokers have issued twelve-month price targets for Exact Sciences' stock. Their EXAS share price targets range from $73.00 to $130.00. On average, they expect the company's share price to reach $96.56 in the next year. This suggests a possible upside of 44.1% from the stock's current price. View analysts price targets for EXAS or view top ...Exact Sciences Corporation Common Stock (EXAS) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets.Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2023 financial results after ...

Exact Sciences (EXAS) delivered earnings and revenue surprises of 46.84% and 11.06%, respectively, for the quarter ended March 2023. ... is selling $2 billion of stock in Las Vegas Sands Corp. so ...Stock EXAS November 21, 2023 NASDAQ 20 minutes delay ... At Exact Sciences, our mission is to eradicate cancer and the suffering it causes — through tests that help prevent it, detect it earlier ...Mar 2, 2023 · In my May 2022 article on Exact Sciences Corporation (NASDAQ:EXAS), titled "Exact Sciences Won't Likely Escape Consolidation in the Industry," I pointed out the need for the company to turn its ... The number of shares outstanding of the Registrant’s $0.01 par value Common Stock as of February 20, 2023 was178,217,142. ... EXACT SCIENCES CORPORATION ANNUAL REPORT ON FORM 10‑K YEAR ENDED DECEMBER 31, 2022 TABLE OF CONTENTS Page No. Part I Item 1. Business 4 Item 1A. Risk Factors 19Find real-time EXAS - Exact Sciences Corp stock quotes, company profile, news and forecasts from CNN Business. Exact Sciences Corporation (NASDAQ:EXAS) Q4 2022 Earnings Conference Call February 21, 2023 5:00 PM ETCompany Participants. Megan Jones - Investor Relations. Kevin Conroy - Chairman and Chief ...

On November 30, 2023, Exact Sciences Corporation (NASDAQ:EXAS) stock closed at $64.00 per share. One-month return of Exact Sciences Corporation (NASDAQ:EXAS) was -4.51%, and its shares gained 38. ...View the latest Exact Sciences Corp. (EXAS) stock price, news, historical charts, analyst ratings and financial information from WSJ.

May 18, 2023 · On May 17, 2023, Exact Sciences Corporation (NASDAQ:EXAS) stock closed at $78.63 per share. One-month return of Exact Sciences Corporation (NASDAQ:EXAS) was 18.54%, and its shares gained 45.61% of ... Exact Sciences Corp. (EXAS) will release its next earnings report on Feb 20, 2024. In the last quarter Exact Sciences Corp. reported -$0.471 EPS in relation to $0 expected by the market. ... Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including ...26-Apr-2022 ... MADISON, Wis., April 26, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leader in advanced cancer diagnostics, today announced that ...Exact Sciences Co. (NASDAQ:EXAS) has garnered attention in the investment world, as Sanders Morris Harris LLC recently acquired a new position in the company during the second quarter of this year. The firm purchased 5,000 shares of Exact Sciences’ stock, with an approximate value of $467,000. This move by Sanders Morris Harris LLC indicates ...Exact Sciences Corp. 65.13. Delayed Data. As of Nov 21. -2.15 / -3.20%. Today’s Change. 40.73. Today ||| 52-Week Range. 100.77.Get the latest information on Exact Sciences Corp (EXAS), a biotechnology company that develops and sells diagnostic tests for cancer screening and treatment. See its stock price, financial performance, earnings, balance sheet, cash flow, and more.On November 30, 2023, Exact Sciences Corporation (NASDAQ:EXAS) stock closed at $64.00 per share. One-month return of Exact Sciences Corporation (NASDAQ:EXAS) was -4.51%, and its shares gained 38. ...

Exact Sciences (EXAS) delivered earnings and revenue surprises of 46.84% and 11.06%, respectively, for the quarter ended March 2023. ... is selling $2 billion of stock in Las Vegas Sands Corp. so ...

Exact Sciences is best known for Cologuard, a non-invasive colorectal cancer screening test that uses stool samples to look for cancerous cells. The company also has tests to detect liver cancer. Find the latest Exact Sciences Corporation (EXAS) stock quote, history, news and other vital information to help you with your stock trading and ...

Complete Exact Sciences Corp. stock information by Barron's. View real-time EXAS stock price and news, along with industry-best analysis. Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2023 financial results after ...03-Nov-2023 ... everyone excited? Whoo. The stock is up. That's good. ... Exact Sciences and chairman and CEO Kevin Conroy. ... sciences commitment to earlier ...Exact Sciences Corporation (EXAS) Shares Pulled Back in Q3. Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” third quarter 2023 investor letter.Historical daily share price chart and data for Exact Sciences since 2001 adjusted for splits and dividends. The latest closing stock price for Exact ...Complete Exact Sciences Corp. stock information by Barron's. View real-time EXAS stock price and news, along with industry-best analysis.Aug 2, 2023Shares of Exact Sciences ( EXAS 0.93%) stormed higher by 16.5% over the first three and a half days of trading this week, according to data provided by S&P Global Market Intelligence. The big gain ...

Exact Sciences Corporation Raises Revenue Guidance for the Full Year 2023. Nov 02 + 1 more update. Forecast to breakeven in 2025 Oct 26. No longer forecast ... Lead Independent Director exercised options to buy US$363k worth of stock. Jan 19. Insider notifies of intention to sell stock Jan 13. An Intrinsic Calculation For Exact ...Transcript : Exact Sciences Corporation Presents at Baird's Global Healthcare Conference 2023, Sep-12-2023 10:50 AM Sep. 12: CI Exact Sciences Corporation acquired Resolution Bioscience, Inc. from Agilent Technologies, Inc. (NYSE:A) for approximately $54.2 million. Sep. 11: CIExact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2023 financial results after ...Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2023 financial results after ...Instagram:https://instagram. argentina etfamazon buy or sellis fisher investments worth the feeinvesting in films Aug 2, 2023 nyse we newsex divident date Share Price. EXACT Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer. It developed Cologuard, a screening test for the ...© Exact Sciences Corporation – 5505 Endeavor Lane - Madison, WI 53719 Powered By Q4 Inc. 5.111.2.6 5.111.2.6 best stock under 100 23-Feb-2023 ... Exact Sciences Corporation Logo (PRNewsfoto/EXACT SCIENCES CORP). The 2030 ... The offer and sale of the 2030 Notes and any shares of common stock ...Jun 7, 2023 · The company's screening revenue (including laboratory services for Cologuard) saw an even more significant growth of 45% year over year. While Exact Sciences remains unprofitable, there was major ...